InvestorsHub Logo
Followers 55
Posts 13535
Boards Moderated 0
Alias Born 10/12/2006

Re: None

Thursday, 11/17/2016 10:55:12 PM

Thursday, November 17, 2016 10:55:12 PM

Post# of 2028
Shares of clinical-stage biopharma Cara Therapeutics (NASDAQ: CARA) soared over 25% higher on Wednesday after analysts at Piper Jaffray upgraded their price target to $21 per share. Analyst Charles Duncan raised the price target for Cara Therapeutics after meeting with management and confirming his confidence in due diligence conducted with respect to the company's clinical programs. CARA closed up over 20% at $12.20 trading over 5.5 Million shares by the market close.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CARA News